Axim Biotechnologies Stock Probability of Future Pink Sheet Price Finishing Over 0.033
| AXIM Stock | USD 0 0 50.00% |
Axim |
Axim Biotechnologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Axim Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Axim Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Axim Biotechnologies is way too risky over 90 days horizon | |
| Axim Biotechnologies has some characteristics of a very speculative penny stock | |
| Axim Biotechnologies appears to be risky and price may revert if volatility continues | |
| Axim Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K. | |
| Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations. | |
| Roughly 41.0% of Axim Biotechnologies shares are held by company insiders |
Axim Biotechnologies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Axim Pink Sheet often depends not only on the future outlook of the current and potential Axim Biotechnologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Axim Biotechnologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 138.1 M |
Axim Biotechnologies Technical Analysis
Axim Biotechnologies' future price can be derived by breaking down and analyzing its technical indicators over time. Axim Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Axim Biotechnologies. In general, you should focus on analyzing Axim Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Axim Biotechnologies Predictive Forecast Models
Axim Biotechnologies' time-series forecasting models is one of many Axim Biotechnologies' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Axim Biotechnologies' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Axim Biotechnologies
Checking the ongoing alerts about Axim Biotechnologies for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Axim Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Axim Biotechnologies is way too risky over 90 days horizon | |
| Axim Biotechnologies has some characteristics of a very speculative penny stock | |
| Axim Biotechnologies appears to be risky and price may revert if volatility continues | |
| Axim Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| Axim Biotechnologies currently holds 5.06 M in liabilities with Debt to Equity (D/E) ratio of 1.36, which is about average as compared to similar companies. Axim Biotechnologies has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Axim Biotechnologies until it has trouble settling it off, either with new capital or with free cash flow. So, Axim Biotechnologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axim Biotechnologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axim to invest in growth at high rates of return. When we think about Axim Biotechnologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K. | |
| Axim Biotechnologies currently holds about 65.16 K in cash with (2.49 M) of positive cash flow from operations. | |
| Roughly 41.0% of Axim Biotechnologies shares are held by company insiders |
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.